Elisabeth Sthengel

NOLabs AB is a holding company that explores and develops proprietary therapies for diabetic patients where current treatment options are insufficient or complicated. It is a medical device company that focuses on its core technology, as well as the development of therapeutic applications for diabetic pain relief. Its product contains NitroSense Nitric Oxide (NO) delivery system and is a multilayer patch that is designed to release NO in a controlled manner. The firm core concept of NitroSense Technology is combining a substance and a delivery system to create h products for local delivery of NO. The company was founded in 2004 and is headquartered in Helsingborg, Sweden.